Targeting pericranial nerve branches to treat migraine: Current approaches and perspectives

Cephalalgia

Volumn 35, Issue 14, 2015, Pages 1308-1322

  Ambrosini, Anna ^a   D'Alessio, Carmelo ^a   Magis, Delphine ^b   Schoenen, Jean ^b  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

blocks; Migraine; neurostimulation; pericranial nerves; surgery; treatment

Indexed keywords

ANTIMIGRAINE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL EFFECTIVENESS; DEVICE SAFETY; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; IMPLANTABLE NEUROSTIMULATOR; MIGRAINE; NERVE DECOMPRESSION; NERVE STIMULATION; OCCIPITAL NERVE STIMULATION; PAIN; PAIN INTENSITY; PARESTHESIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERICRANIAL NERVE STIMULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ALLERGY; SUPRAORBITAL NERVE STIMULATION; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; ANIMAL; CRANIAL NERVE; ELECTROTHERAPY; MIGRAINE DISORDERS; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PROCEDURES; TRENDS;

ANIMALS; CRANIAL NERVES; ELECTRIC STIMULATION THERAPY; HUMANS; MIGRAINE DISORDERS; PERIPHERAL NERVES; TREATMENT OUTCOME;

EID: 84946809752     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102415573511     Document Type: Review

References (85)

1. Merikangas KR,. Contributions of epidemiology to our understanding of migraine. Headache 2013; 53: 230-246.
2. Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: Results from the American Migraine Prevalence and Prevention study. Headache 2012; 52: 3-17.
3. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41: 646-657.
4. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808.
5. Edvinsson L, Villalin CM, MaassenVanDenBrink A,. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012; 136: 319-333.
6. Leao AAP,. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 359-390.
7. Lauritzen M,. Cortical spreading depression in migraine. Cephalalgia 2001; 21: 757-760.
8. Akerman S, Holland PR, Goadsby PJ,. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011; 12: 570-584.
9. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. Neurology 2003; 60: 935-940.
10. Kelman L,. The premonitory symptoms (prodrome): A tertiary care study of 893 migraineurs. Headache 2004; 44: 865-872.
11. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 2014; 137: 232-241.
12. De Tommaso M, Ambrosini A, Brighina F, et al. Altered sensory processing in migraine. Nat Rev Neurol 2014; 10: 144-155.
13. Montagna P, Cortelli P, Monari L, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 1994; 44: 666-669.
14. Welch KM, Levine SR, D'Andrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989; 39: 538-541.
15. Reyngoudt H, Paemeleire K, Descamps B, et al. 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. Cephalalgia 2011; 31: 1243-1253.
16. Sándor P, Ambrosini A, Agosti RM, et al. Genetics of migraine: Possible links to neurophysiological abnormalities. Headache 2002; 42: 365-377.
17. Sprenger T, Borsook D,. Migraine changes the brain: Neuroimaging makes its mark. Curr Opin Neurol 2012; 25: 252-262.
18. Coppola G, Schoenen J,. Cortical excitability in chronic migraine. Curr Pain Headache Rep 2012; 16: 93-100.
19. Lous I, Olesen J,. Evaluation of pericranial tenderness and oral function in patients with common migraine, muscle contraction headache and 'combination headache'. Pain 1982; 12: 385-393.
20. Calandre EP, Hidalgo J, García-Leiva JM, et al. Trigger point evaluation in migraine patients: An indication of peripheral sensitization linked to migraine predisposition? Eur J Neurol 2006; 13: 244-249.
21. Seo BF, Jung SN, Sohn WI, et al. Lymph node compression of the lesser occipital nerve: A cause of migraine. J Plast Reconstr Aesthet Surg 2011; 64: 1657-1660.
22. Schueler M, Neuhuber WL, De Col R, et al. Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents. Headache 2014; 54: 996-1009.
23. Schueler M, Messlinger K, Dux M, et al. Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache. Pain 2013; 154: 1622-1631.
24. Bigal ME, Lipton RB,. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 2009; 13: 301-307.
25. Whyte CA, Tepper SJ,. Adverse effects of medications commonly used in the treatment of migraine. Expert Rev Neurother 2009; 9: 1379-1391.
26. Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. Headache 2007; 47: 65-72.
27. Zeeberg P, Olesen J, Jensen R,. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia 2006; 26: 1192-1198.
28. Melzack R, Wall PD,. Pain mechanisms: A new theory. Science 1965; 150: 971-979.
29. DeSantana JM, Da Silva LF, De Resende MA, et al. Transcutaneous electrical nerve stimulation at both high and low frequencies activates ventrolateral periaqueductal grey to decrease mechanical hyperalgesia in arthritic rats. Neuroscience 2009; 163: 1233-1241.
30. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007; 14: 952-970.
31. Weiner RL, Reed KL,. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999; 2: 217-222.
32. Magis D, Schoenen J,. Advances and challenges in neurostimulation for headaches. Lancet Neurol 2012; 11: 708-719.
33. Lipton R, Goadsby P, Cady R, et al. PRISM study: Occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009; 29 (Suppl 1): 30-30.
34. Saper JR, Dodick DW, Silberstein SD, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011; 31: 271-285.
35. Silberstein S, Dodick D, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012; 32: 1165-1179.
36. Dodick D, Silberstein S, Huh B, et al. Evidence for long-term efficacy of peripheral nerve stimulation of occipital nerves in the management of chronic migraine. Cephalalgia 2013; 33 (Suppl): 58-58.
37. Slotty P, Bara G, Kowatz L, et al. Occipital nerve stimulation for chronic migraine: A randomized trial on subthreshold stimulation. Cephalalgia 2015; 35: 73-78.
38. Reed KL, Black SB, Banta CJ 2nd, et al. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: Initial experience. Cephalalgia 2010; 30: 260-271.
39. Reed KL, Will KR, Chapman J, et al. Combined occipital and supraorbital neurostimulation for chronic migraine headaches: An extended case series. Cephalalgia 2011; 31 (Suppl 1): 98-98.
40. Lenaerts ME, Oommen KJ, Couch JR, et al. Can vagus nerve stimulation help migraine? Cephalalgia 2008; 28: 392-395.
41. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology 2013; 80: 697-704.
42. Magis D, Sava S, d'Elia TS, et al. Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: A survey of 2,313 headache sufferers in the general population. J Headache Pain 2013; 14: 95-95.
43. Goadsby P, Grosberg B, Mauskop A, et al. Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia 2014; 34: 986-993.
44. Silberstein SD, Neves da Silva A, Calhoun AH, et al. Non-invasive vagus nerve stimulation for chronic migraine prevention in a prospective, randomized, sham-controlled pilot study (the EVENT study): Report from the double-blind phase. Late Breaking Poster 19 at the 56th Annual Scientific Meeting of the American Headache Society, Los Angeles, CA, USA, 26-29 June 2014.
45. Silberstein SD, Neves da Silva A, Calhoun AH, et al. Chronic migraine prevention with non-invasive vagus nerve stimulation in a prospective pilot study (the EVENT study): Report from the open-label phase. Late Breaking Poster 21 at the 56th Annual Scientific Meeting of the American Headache Society, Los Angeles, CA, USA, 26-29 June 2014.
46. Goadsby PJ, Schoenen J, Ferrari MD, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006; 26: 1168-1170.
47. Paemeleire K, Van Buyten JP, Van Buynder M, et al. Phenotype of patients responsive to occipital nerve stimulation for refractory head pain. Cephalalgia 2010; 30: 662-673.
48. Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: Position statement from the European Headache Federation. J Headache Pain 2013; 14: 86-86.
49. Meissner K, Fassler M, Rucker G, et al. Differential effectiveness of placebo treatments: A systematic review of migraine prophylaxis. JAMA Intern Med 2013; 173: 1941-1951.
50. Kerr FWL,. A mechanism to account for frontal headache in cases of posterior fossa tumour. J Neurosurg 1961; 18: 605-609.
51. Saadah HA, Taylor FB,. Sustained headache syndrome associated with tender occipital nerve zones. Headache 1987; 27: 201-205.
52. Anthony M,. Headache and the greater occipital nerve. Clin Neurol Neurosurg 1992; 94: 297-301.
53. Gawel MJ, Rothbart PJ,. Occipital nerve block in the management of headache and cervical pain. Cephalalgia 1992; 12: 9-13.
54. Caputi CA, Firetto V,. Therapeutic blockade of greater occipital and supraorbital nerves in migraine patients. Headache 1997; 37: 174-179.
55. Afridi SK, Shields KG, Bhola R, et al. Greater occipital nerve injection in primary headache syndromes-prolonged effects from a single injection. Pain 2006; 122: 126-129.
56. Ashkenazi A, Matro R, Shaw JW, et al. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: A randomised comparative study. J Neurol Neurosurg Psychiatry 2008; 79: 415-417.
57. Takmaz SA, Inan N, Uçler S, et al. Greater occipital nerve block in migraine headache: Preliminary results of 10 patients. Agri 2008; 20: 47-50.
58. Tobin JA, Flitman SS,. Occipital nerve blocks: Effect of symptomatic medication: Overuse and headache type on failure rate. Headache 2009; 49: 1479-1485.
59. Weibelt S, Andress-Rothrock D, King W, et al. Suboccipital nerve blocks for suppression of chronic migraine: Safety, efficacy, and predictors of outcome. Headache 2010; 50: 1041-1044.
60. Gelfand AA, Reider AC, Goadsby PJ,. Outcomes of greater occipital nerve injections in pediatric patients with chronic primary headache disorders. Pediatr Neurol 2014; 50: 135-139.
61. Dilli E, Halker R, Vargas B, et al. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. Cephalalgia. Epub ahead of print 12 December 2014. DOI: 10.1177/0333102414561872.
62. Inan LE, Inan N, Karadas O, et al. Greater occipital nerve blocks with bupivacaine in the treatment of chronic migraine. Randomized, multicenter, double-blind, parallel, placebo-controlled study. Eur J Neurol 2014; 21 (S1): 52-52.
63. Bovim G, Sand T,. Cervicogenic headache, migraine without aura and tension-type headache. Diagnostic blockade of greater occipital and supra-orbital nerves. Pain 1992; 51: 43-48.
64. Ashkenazi A, Young WB,. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache 2005; 45: 350-354.
65. Young W, Cook B, Malik S, et al. The first 5 minutes after greater occipital nerve block. Headache 2008; 48: 1126-1128.
66. Baron EP, Tepper SJ, Mays M, et al. Acute treatment of basilar-type migraine with greater occipital nerve blockade. Headache 2010; 50: 1057-1059.
67. Ilhan Alp S, Alp R,. Supraorbital and infraorbital nerve blockade in migraine patients: Results of 6-month clinical follow-up. Eur Rev Med Pharmacol Sci 2013; 17: 1778-1781.
68. Knight G,. Surgical treatment of migraine. Proc R Soc Med 1962; 55: 172-176.
69. Guyuron B, Varghai A, Michelow BJ, et al. Corrugator supercilii muscle resection and migraine headaches. Plast Reconstr Surg 2000; 106: 429-434.
70. Guyuron B, Tucker T, Davis J,. Surgical treatment of migraine headaches. Plast Reconstr Surg 2002; 109: 2183-2189.
71. Guyuron B, Kriegler JS, Davis J, et al. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 2005; 115: 1-9.
72. Dirnberger F, Becker K,. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg 2004; 114: 652-657.
73. Poggi JT, Grizzell BE, Helmer SD,. Confirmation of surgical decompression to relieve migraine headaches. Plast Reconstr Surg 2008; 122: 115-122.
74. Guyuron B, Reed D, Kriegler JS, et al. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg 2009; 124: 461-468.
75. Guyuron B, Kriegler JS, Davis J, et al. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg 2011; 127: 603-608.
76. Larson K, Lee M, Davis J, et al. Factors contributing to migraine headache surgery failure and success. Plast Reconstr Surg 2011; 128: 1069-1075.
77. de Ru JA, Schellekens PP, Lohuis PJ,. Corrugator supercilii transection for headache emanating from the frontal region: A clinical evaluation of ten patients. J Neural Transm 2011; 118: 1571-1574.
78. Liu MT, Armijo BS, Guyuron B,. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg 2012; 129: 413-419.
79. Chepla KJ, Oh E, Guyuron B,. Clinical outcomes following supraorbital foraminotomy for treatment of frontal migraine headache. Plast Reconstr Surg 2012; 129: 656e-662e.
80. Lee M, Monson MA, Liu MT, et al. Positive botulinum toxin type a response is a prognosticator for migraine surgery success. Plast Reconstr Surg 2013; 131: 751-757.
81. Chmielewski L, Liu MT, Guyuron B,. The role of occipital artery resection in the surgical treatment of occipital migraine headaches. Plast Reconstr Surg 2013; 131: 351e-356e.
82. D'Amico D, Leone M, Bussone G,. Side-locked unilaterality and pain localization in long-lasting headaches: Migraine, tension-type headache, and cervicogenic headache. Headache 1994; 34: 526-530.
83. Jackson JL, Kuriyama A, Hayashino Y,. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis. JAMA 2012; 307: 1736-1745.
84. Delstanche S, Schoenen J,. Botulinum toxin for the treatment of headache: A promising path on a “dead end road� Acta Neurol Belg 2010; 110: 221-229.
85. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936.